Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Pushes Faster Post-Approval Study Starts In Drug-Eluting Stent Guidance

This article was originally published in The Gray Sheet

Executive Summary

FDA's March 26 1draft guidance on nonclinical and clinical studies of drug-eluting coronary stents is the first device guidance to recommend that sponsors begin post-market studies before their device is approved
Advertisement

Related Content

FDA Previews Final Drug-Eluting Stent Guidance
FDA Previews Final Drug-Eluting Stent Guidance
Pre-Clinical Testing Issues Spark Questions From DES Manufacturers
Pre-Clinical Testing Issues Spark Questions From DES Manufacturers
Major Trials On Dual-Antiplatelet Therapy For DES In The Works
Major Trials On Dual-Antiplatelet Therapy For DES In The Works
Industry Presents Wish List For DES Guidance At CRT Conference
Off-Label Drug-Eluting Stent Data Weak; Label Should Be Revised – Panel
Taxus “Peri-approval” Trial Offers Postmarket Study Model – Zuckerman
Taxus “Peri-approval” Trial Offers Postmarket Study Model – Zuckerman
Advertisement
UsernamePublicRestriction

Register

MT025942

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel